Literature DB >> 8378959

Impairment of anti-platelet-aggregating activity of endothelial cells after experimental subarachnoid hemorrhage.

H Ohkuma1, K Ogane, S Fujita, H Manabe, S Suzuki.   

Abstract

BACKGROUND AND
PURPOSE: Serial changes of anti-platelet-aggregating activity in the endothelial cells after experimental subarachnoid hemorrhage were studied in 30 feline two-hemorrhage models.
METHODS: One hour or 2, 4, 7, or 14 days after mimic subarachnoid hemorrhage, ADP (40 mg/kg) was infused into the basilar artery via the right vertebral artery to activate circulating platelets. Immediately after ADP infusion, the basilar artery was fixed by intra-arterial perfusion with 1.5% glutaraldehyde in 0.1 mol/L phosphate buffer and was removed. The luminal surface was examined under a scanning electron microscope.
RESULTS: One hour after subarachnoid hemorrhage, no platelets adhered or aggregated on the luminal surface. However, 4 to 7 days after subarachnoid hemorrhage, many platelets were observed adhering or aggregating on the luminal surface.
CONCLUSIONS: These findings suggest the impairment of anti-platelet-aggregating activity of endothelial cells after subarachnoid hemorrhage. This impairment may be involved in inducing cerebral ischemia during cerebral vasospasm by causing platelet adhesion and aggregation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378959     DOI: 10.1161/01.str.24.10.1541

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

Review 1.  Cerebral vasospasm: a consideration of the various cellular mechanisms involved in the pathophysiology.

Authors:  Jacob Hansen-Schwartz
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

2.  In vitro analysis of platelet function in acute aneurysmal subarachnoid haemorrhage.

Authors:  Christian von der Brelie; Alexander Subai; Verena Limperger; Veit Rohde; Astrid Dempfle; Azize Boström
Journal:  Neurosurg Rev       Date:  2017-07-24       Impact factor: 3.042

3.  Safety of preprocedural antiplatelet medication in coil embolization of ruptured cerebral aneurysms at the acute stage.

Authors:  Norihito Shimamura; Masato Naraoka; Naoya Matsuda; Hiroki Ohkuma
Journal:  Interv Neuroradiol       Date:  2014-08-28       Impact factor: 1.610

Review 4.  The role of arterioles and the microcirculation in the development of vasospasm after aneurysmal SAH.

Authors:  Masato Naraoka; Naoya Matsuda; Norihito Shimamura; Kenichiro Asano; Hiroki Ohkuma
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

5.  Embolic signals during routine transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage.

Authors:  Fernando Mendes Paschoal; Karla de Almeida Lins Ronconi; Marcelo de Lima Oliveira; Ricardo de Carvalho Nogueira; Eric Homero Albuquerque Paschoal; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo; Edson Bor-Seng-Shu
Journal:  Biomed Res Int       Date:  2015-03-29       Impact factor: 3.411

6.  Platelet activation and aggregation after aneurysmal subarachnoid hemorrhage.

Authors:  Pauline Perez; Anne-Claire Lukaszewicz; Stephanie Lenck; Rémy Nizard; Ludovic Drouet; Didier Payen
Journal:  BMC Neurol       Date:  2018-04-28       Impact factor: 2.474

Review 7.  Antiplatelet therapy for aneurysmal subarachnoid haemorrhage.

Authors:  S M Dorhout Mees; W M van den Bergh; A Algra; G J E Rinkel
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 8.  Role of platelets in the pathogenesis of delayed injury after subarachnoid hemorrhage.

Authors:  Ari Dienel; Peeyush Kumar T; Spiros L Blackburn; Devin W McBride
Journal:  J Cereb Blood Flow Metab       Date:  2021-06-10       Impact factor: 6.960

9.  Effects of post-interventional antiplatelet therapy on angiographic vasospasm, delayed cerebral ischemia, and clinical outcome after aneurysmal subarachnoid hemorrhage: a single-center experience.

Authors:  Claudia Ditz; Björn Machner; Hannes Schacht; Alexander Neumann; Peter Schramm; Volker M Tronnier; Jan Küchler
Journal:  Neurosurg Rev       Date:  2021-01-25       Impact factor: 3.042

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.